A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Aboody, Karen S., M.D. Bookmark and Share

Laboratory of Karen S. Aboody, M.D.

Neural Stem Cell-Mediated Cancer Treatment

Overview: Neural stem cells (NSCs) have a natural ability to home to malignant tumors and invasive tumor cells, making them an ideal delivery vehicle for transporting therapeutic agents to tumor sites.  Dr. Aboody and colleagues at COH were the first in the world to move this therapeutic strategy from “bench to bedside” for brain tumor patients, demonstrating safety of their NSCs. 
 
My translational research laboratory focuses on neural stem cells (NSCs) and their therapeutic applications for primary and metastatic tumors. Our novel findings have demonstrated the inherent tumor-tropic property of NSCs, and their use as cellular delivery vehicles to effectively target and deliver therapeutic payloads to invasive tumor sites, including brain tumors and metastatic cancers. Their capacity for tracking infiltrating tumor cells and localizing to distant micro-tumor foci make NSCs a novel and attractive tumor selective delivery vehicle with tremendous clinical potential. In effect, the NSCs serve as a platform for tumor-localized therapy, which should also minimize toxicity to normal tissues. Our current research focuses on modifying human NSCs to deliver different therapeutic agents to tumor sites in animal models.
 
Clinical Trials: In 2013, we completed a first in-human FDA approved safety/feasibility NSC clinical trial at City of Hope in patients with recurrent high-grade gliomas (clinical PI: Dr. Jana Portnow, MD).  The NSCs delivered an enzyme (cytosine deaminase; CD) that converts an inactive prodrug (5-flurocytosine; 5-FC) to an active chemotherapeutic agent (5-Flurouracil; 5-FU).  The 5-FU produced by the NSCs diffuses into surrounding brain tumor tissue, selectively killing dividing tumor cells.  By producing the chemo drug only at the tumor sites, systemic side effects are minimized.  Results of this study demonstrated: 1) safety of administering therapeutic NSCs into the brain tumor resection cavity or biopsy site; 2) proof of concept for tumor-localized chemotherapy production – demonstrating that the CD-expressing NSCs were able to convert oral 5-FC to the active chemo drug 5-FU, locally in the brain; and 3) no significant immune response following one round of treatment.  A phase I dose escalation, multi-treatment round study is currently accruing patients at COH.
 
Active Research
1. NSCs delivering a prodrug activating enzyme for tumor-localized chemotherapy production:   CD-NSCs + 5-FC → 5-FU
Funding: STOP Cancer, COH, The Rosalinde and Arthur Gilbert Foundation, The Ziman  Family  Foundation, NIH-NCI (Portnow, Aboody)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NSCs are genetically modified to express cytosine deaminase (CD).  When the inactive prodrug 5-FC is administered, it crosses the BBB and gets converted to the active chemotherapeutic 5-FU by the CD expressing NSCs locally at the brain tumor sites.  In effect, allowing for tumor localized chemotherapy production, and reducing toxic side effects to normal tissues.
 

2. NSCs delivering a prodrug activating enzyme for tumor-localized chemotherapy production:   CE-NSCs + IRN → SN-38
Funding:  California Institute of Regenerative Medicine, NIH-U01, The Rosalinde and Arthur Gilbert Foundation, STOP Cancer, Mary Kay Foundation (Berlin, Aboody)
 
NSC-mediated CE/Irinotecan (CPT-11) enzyme/prodrug therapy.  NSCs localize to metastatic tumor sites and express the CE enzyme. CE converts the intravenously administered CPT-11 (irinotecan) prodrug to the active chemotherapeutic drug SN-38.  SN-38 is highly toxic to the surrounding tumor cells
 
In 2010, we were granted an $18M CIRM Disease Team Award to move a 2nd generation enzyme/prodrug therapeutic toward clinical trials (Co-PIs:  Jana Portnow, MD and Larry Couture, PhD). Collaborators include the Synold lab for pharmacology, the Barish lab for 3D tumor reconstruction, the Forman lab (C Brown) for xenogen imaging and tumor modeling, and the Moats lab at Children’s Hospital Los Angeles for MRI imaging. We also work closely with the Center for Biomedicine & Genetics and the Office of IND Development and Regulatory Affairs. An IND has been submitted and we expect to initiate a phase I study for this NSC-mediated brain tumor therapy in 2015.  We are also funded $4.7M by an NIH-U01 (in collaboration with CHLA and St. Jude) to move this same product to clinical trial for pediatric patients with metastatic neuroblastoma by 2017.
 

3. NSCs delivering internalized gold nanoparticles for thermal ablative therapy
in collaboration with Jacob Berlin laboratory, COH
 
After loading NSCs with gold nanorods (NSC-AuNPs), they are administered (current preclinical investigations focusing on bladder and prostate cancer).  Following migration of NSCs to tumor  sites, localizing the gold particles, near infrared laser is applied, causing the gold nanoparticles to  vibrate and generate heat – ‘burning’ surrounding tumor tissue.
Funding:  COH, The Rosalinde and Arthur Gilbert Foundation, STOP Cancer, Alvarez Family  Charitable Foundation, Mary Kay Foundation (Berlin, Aboody), Ladies Auxiliary Veteran’s Grant (Mooney)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. NSCs delivering external nanoparticles for small molecule drug delivery
in collaboration with Jacob Berlin laboratory, COH
   
In collaboration with Dr. Berlin we are constructing NSC-NP hybrids, where the NPs are being  constructed to release drug after NSCs reach the tumor.  The NPs will be externally bound to the  NSCs.  Our initial preclinical studies are focused on peritoneal ovarian cancer metastases, for  potential translation tp patients with Stage III ovarian carcinoma.
Funding: COH, Anthony F. & Susan M. Markel Fund, NIH, The Rosalinde and Arthur Gilbert Foundation,  STOP Cancer, Alvarez Family Charitable Foundation. Ladies Auxillary Veteran’s Grant (R Mooney)
 
 
 
 
 
 
 
 
 
 
 
 
5. NSC Oncolytic Virotherapy
in collaboration with Maciej Lesniak laboratory, University of Chicago
Funding: NIH-U01 (PI, Lesniak)
 
We are further modifying our clinically relevant NSC line to produce conditionally replication competent oncolytic virus, CRAd-Survivan-pk7, for application to newly diagnosed glioma patients.
 

Translational Overview

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Additional research investigations early in the pipeline include:
 
  • NSCs as a platform for production of anti-HER2 Antibody for application to HER2 positive breast cancer brain metastases.
  • Identification of factors involved in NSC-tumor tropism.
  • Investigating efficiency of NSC-tumor tropism following various routes of administration (intracranial, intravenous, intraperitoneal, intranasal).
 

Karen S. Aboody, M.D. Lab Members

Aboody Lab 2015
 
Margarita Gutova, M.D.
Associate Research Professor

Rachael Mooney, Ph.D.
Post-doctoral CIRM Scholar
 
Marianne Metz
Staff Scientist, Lab Manager
 
Soraya Aramburo
Research Associate II, Small Animal Surgery Supervisor

Zhongqi Li, Ph.D.
Research Associate II

Revathiswari Tirughana-Samban, B.S.
Research Associate II
 
Diana Oganesyan
Research Technician
 
Ali-Asghar Zhumkhawala, MD
Urology Surgical Research Fellow
 
Monika Polewski,
City of Hope Graduate Student
 
Elena Chavez
CIRM Masters Intern, CSU Pomona
 
Ugochi Nwokafor
CIRM Masters Intern, CSU Channel Islands
 
Alberto Herrera
CIRM Intern, CSU Pomona
 
Elizabeth Ochoa
Senior Secretary, Dr. Aboody
 

Aboody, Karen S., M.D.

Laboratory of Karen S. Aboody, M.D.

Neural Stem Cell-Mediated Cancer Treatment

Overview: Neural stem cells (NSCs) have a natural ability to home to malignant tumors and invasive tumor cells, making them an ideal delivery vehicle for transporting therapeutic agents to tumor sites.  Dr. Aboody and colleagues at COH were the first in the world to move this therapeutic strategy from “bench to bedside” for brain tumor patients, demonstrating safety of their NSCs. 
 
My translational research laboratory focuses on neural stem cells (NSCs) and their therapeutic applications for primary and metastatic tumors. Our novel findings have demonstrated the inherent tumor-tropic property of NSCs, and their use as cellular delivery vehicles to effectively target and deliver therapeutic payloads to invasive tumor sites, including brain tumors and metastatic cancers. Their capacity for tracking infiltrating tumor cells and localizing to distant micro-tumor foci make NSCs a novel and attractive tumor selective delivery vehicle with tremendous clinical potential. In effect, the NSCs serve as a platform for tumor-localized therapy, which should also minimize toxicity to normal tissues. Our current research focuses on modifying human NSCs to deliver different therapeutic agents to tumor sites in animal models.
 
Clinical Trials: In 2013, we completed a first in-human FDA approved safety/feasibility NSC clinical trial at City of Hope in patients with recurrent high-grade gliomas (clinical PI: Dr. Jana Portnow, MD).  The NSCs delivered an enzyme (cytosine deaminase; CD) that converts an inactive prodrug (5-flurocytosine; 5-FC) to an active chemotherapeutic agent (5-Flurouracil; 5-FU).  The 5-FU produced by the NSCs diffuses into surrounding brain tumor tissue, selectively killing dividing tumor cells.  By producing the chemo drug only at the tumor sites, systemic side effects are minimized.  Results of this study demonstrated: 1) safety of administering therapeutic NSCs into the brain tumor resection cavity or biopsy site; 2) proof of concept for tumor-localized chemotherapy production – demonstrating that the CD-expressing NSCs were able to convert oral 5-FC to the active chemo drug 5-FU, locally in the brain; and 3) no significant immune response following one round of treatment.  A phase I dose escalation, multi-treatment round study is currently accruing patients at COH.
 
Active Research
1. NSCs delivering a prodrug activating enzyme for tumor-localized chemotherapy production:   CD-NSCs + 5-FC → 5-FU
Funding: STOP Cancer, COH, The Rosalinde and Arthur Gilbert Foundation, The Ziman  Family  Foundation, NIH-NCI (Portnow, Aboody)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NSCs are genetically modified to express cytosine deaminase (CD).  When the inactive prodrug 5-FC is administered, it crosses the BBB and gets converted to the active chemotherapeutic 5-FU by the CD expressing NSCs locally at the brain tumor sites.  In effect, allowing for tumor localized chemotherapy production, and reducing toxic side effects to normal tissues.
 

2. NSCs delivering a prodrug activating enzyme for tumor-localized chemotherapy production:   CE-NSCs + IRN → SN-38
Funding:  California Institute of Regenerative Medicine, NIH-U01, The Rosalinde and Arthur Gilbert Foundation, STOP Cancer, Mary Kay Foundation (Berlin, Aboody)
 
NSC-mediated CE/Irinotecan (CPT-11) enzyme/prodrug therapy.  NSCs localize to metastatic tumor sites and express the CE enzyme. CE converts the intravenously administered CPT-11 (irinotecan) prodrug to the active chemotherapeutic drug SN-38.  SN-38 is highly toxic to the surrounding tumor cells
 
In 2010, we were granted an $18M CIRM Disease Team Award to move a 2nd generation enzyme/prodrug therapeutic toward clinical trials (Co-PIs:  Jana Portnow, MD and Larry Couture, PhD). Collaborators include the Synold lab for pharmacology, the Barish lab for 3D tumor reconstruction, the Forman lab (C Brown) for xenogen imaging and tumor modeling, and the Moats lab at Children’s Hospital Los Angeles for MRI imaging. We also work closely with the Center for Biomedicine & Genetics and the Office of IND Development and Regulatory Affairs. An IND has been submitted and we expect to initiate a phase I study for this NSC-mediated brain tumor therapy in 2015.  We are also funded $4.7M by an NIH-U01 (in collaboration with CHLA and St. Jude) to move this same product to clinical trial for pediatric patients with metastatic neuroblastoma by 2017.
 

3. NSCs delivering internalized gold nanoparticles for thermal ablative therapy
in collaboration with Jacob Berlin laboratory, COH
 
After loading NSCs with gold nanorods (NSC-AuNPs), they are administered (current preclinical investigations focusing on bladder and prostate cancer).  Following migration of NSCs to tumor  sites, localizing the gold particles, near infrared laser is applied, causing the gold nanoparticles to  vibrate and generate heat – ‘burning’ surrounding tumor tissue.
Funding:  COH, The Rosalinde and Arthur Gilbert Foundation, STOP Cancer, Alvarez Family  Charitable Foundation, Mary Kay Foundation (Berlin, Aboody), Ladies Auxiliary Veteran’s Grant (Mooney)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. NSCs delivering external nanoparticles for small molecule drug delivery
in collaboration with Jacob Berlin laboratory, COH
   
In collaboration with Dr. Berlin we are constructing NSC-NP hybrids, where the NPs are being  constructed to release drug after NSCs reach the tumor.  The NPs will be externally bound to the  NSCs.  Our initial preclinical studies are focused on peritoneal ovarian cancer metastases, for  potential translation tp patients with Stage III ovarian carcinoma.
Funding: COH, Anthony F. & Susan M. Markel Fund, NIH, The Rosalinde and Arthur Gilbert Foundation,  STOP Cancer, Alvarez Family Charitable Foundation. Ladies Auxillary Veteran’s Grant (R Mooney)
 
 
 
 
 
 
 
 
 
 
 
 
5. NSC Oncolytic Virotherapy
in collaboration with Maciej Lesniak laboratory, University of Chicago
Funding: NIH-U01 (PI, Lesniak)
 
We are further modifying our clinically relevant NSC line to produce conditionally replication competent oncolytic virus, CRAd-Survivan-pk7, for application to newly diagnosed glioma patients.
 

Translational Overview

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Additional research investigations early in the pipeline include:
 
  • NSCs as a platform for production of anti-HER2 Antibody for application to HER2 positive breast cancer brain metastases.
  • Identification of factors involved in NSC-tumor tropism.
  • Investigating efficiency of NSC-tumor tropism following various routes of administration (intracranial, intravenous, intraperitoneal, intranasal).
 

Lab Members

Karen S. Aboody, M.D. Lab Members

Aboody Lab 2015
 
Margarita Gutova, M.D.
Associate Research Professor

Rachael Mooney, Ph.D.
Post-doctoral CIRM Scholar
 
Marianne Metz
Staff Scientist, Lab Manager
 
Soraya Aramburo
Research Associate II, Small Animal Surgery Supervisor

Zhongqi Li, Ph.D.
Research Associate II

Revathiswari Tirughana-Samban, B.S.
Research Associate II
 
Diana Oganesyan
Research Technician
 
Ali-Asghar Zhumkhawala, MD
Urology Surgical Research Fellow
 
Monika Polewski,
City of Hope Graduate Student
 
Elena Chavez
CIRM Masters Intern, CSU Pomona
 
Ugochi Nwokafor
CIRM Masters Intern, CSU Channel Islands
 
Alberto Herrera
CIRM Intern, CSU Pomona
 
Elizabeth Ochoa
Senior Secretary, Dr. Aboody
 
Our Scientists

Our research laboratories are led by the best and brightest minds in scientific research.
 

Beckman Research Institute of City of Hope is internationally  recognized for its innovative biomedical research.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.

Learn more about
City of Hope's institutional distinctions, breakthrough innovations and collaborations.
 
Develop new therapies, diagnostics and preventions in the fight against cancer and other life-threatening diseases.
 
Support Our Research
By giving to City of Hope, you support breakthrough discoveries in laboratory research that translate into lifesaving treatments for patients with cancer and other serious diseases.
 
 
 
 


NEWS & UPDATES
  • It was 2009 when a City of Hope patient in her 40s learned that the cancer she had been fighting for several years had metastasized to her lungs. Her medical team ran genetic tests on the tumor, but none of the drug therapies available at the time targeted the known mutations in the tumor cells. […]
  • Acute myeloid leukemia (AML) is characterized by a rapidly-developing cancer in the myeloid line of blood cells, which is responsible for producing red blood cells, platelets and several types of white blood cells called granulocytes. Because AML grows rapidly, it can quickly crowd out normal blood cells, leadi...
  • Rachel Divine is a yoga therapist and patient leader for the Sheri & Les Biller Patient and Family Resource Center. She’s also a former City of Hope patient. When someone you know has cancer, even the word “cancer” can make you feel nervous, sleepless, depressed or more. But, as a yoga teacher for 15 ...
  •   Diagnosed with type 1 diabetes when she was 9 years old, Gina Marchini accepted the fact that she would need insulin the rest of her life. Every day, she injected herself with the lifesaving hormone. She also carefully controlled her diet and monitored the rise and fall of her blood glucose with military...
  • The defeat of cancer will require a team effort. Nowhere is this more necessary (or apparent) than in efforts to combat two of the most deadly forms of the disease  – pancreatic cancer and triple-negative breast cancer. It’s the approach City of Hope is taking with its newly launched multidisciplinary teams, br...
  • It’s a reasonable question: Why is the National Cancer Institute funding a study on preventing heart failure? The answer is reasonable as well: Rates of heart failure are drastically high among childhood cancer survivors — 15 times higher than among people the same age who were never treated for cancer. T...
  • Many teenagers take a break from academics during the summer, but not the eight high school students enrolled in the California Institute for Regenerative Medicine (CIRM) Creativity Awards program at City of Hope. They took the opportunity to obtain as much hands-on research experience as possible, learning fro...
  • About one in eight women will develop breast cancer at some point in her life. In fact, breast cancer is the most common cancer in American women, behind skin cancer. Although women can’t change some risk factors, such as genetics and the natural aging process, there are certain things they can do to lower thei...
  • As genetic testing becomes more sophisticated, doctors and their patients are finding that such tests can lead to the discovery of previously unknown cancer risks. In his practice at City of Hope, Thomas Slavin, M.D., an assistant clinical professor in the Division of Clinical Cancer Genetics, sees the full spe...
  • And the winners are … everyone in the San Gabriel Valley. The recipients of City of Hope’s first-ever Healthy Living grants have been announced, and the future is looking healthier already. In selecting San Gabriel Valley organizations to receive the grants, City of Hope’s Community Benefits Advisory Council ch...
  • Barry Leshowitz is a former City of Hope patient and a family advisor for the Sheri & Les Biller Patient and Family Resource Center. It’s been almost seven years since I checked into a local hospital in Phoenix for a hip replacement, only to be informed by the surgeon that he had canceled the surgery....
  • When it comes to science, the best graduate schools don’t just train scientists, they prepare their students for a lifetime of learning, accomplishment and positive impact on society. At City of Hope, the Irell & Manella Graduate School of Biological Sciences goes one step further – by preparing students to...
  • Cancer affects not just the cancer patient, but everyone around him or her, even after treatment is complete. The challenges can include the fear of cancer recurrence, coping with cancer’s economic impact and the struggle to achieve work-life balance post-treatment. Family members and loved ones of cancer patie...
  •   Bladder cancer facts: Bladder cancer is a disease in which malignant (cancer) cells form in the tissues of the bladder. 2015 estimates: 74,000 new cases of bladder cancer diagnosed 16,000 deaths from bladder cancer (about 11,510 in men and 4,490 in women) Risk factors for bladder cancer: Smoking: Smokers...
  • Women with ovarian cancer have questions about the most promising treatment options, revolutionary research avenues, survivorship and, of course, the potential impact on their personal lives. Now, together in one place, are experts who can provide answers. On Saturday, Sept. 12, the 2015 Ovarian Cancer Survivor...